Stock Analysis of Annovis Bio Inc (ANVS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ANVS
Close 8.31
Change 0.280 / 3.49 %
Volume 471908
Vol Change 13912.00 / 3.04 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Mild Growth
Value Index No Significant Value
Profitability Index Poor Profitability Stock
Stability Index Good Stability


Fundamental View of Annovis Bio Inc
PE (TTM)

-0.0075

Very Poor
Price / Book

0.0229

Excellent
Price / Sales

0

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

92835.16 K

Enterprise Value

-5661.88 M

ROA (TTM)

-173.44

Very Poor
ROE (TTM)

-305.64

Very Poor
Net Margin (TTM)

0

Poor
Revenue

%

0
Net Profit

65.90 %

-41717.09 K
Debt to Equity

0

Excellent
Altman Z Score

-15.13

Very Poor
Quick Ratio

0

Poor
Cash Ratio

1.34

Indecisive


Highs/Lows of Annovis Bio Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week5.93 40.13 % 1.54 % 10.46.1715-May-2413-May-24
Two Week5.18 60.42 % 3.42 % 10.44.7915-May-2408-May-24
One Month8.99 7.56 % 5.60 % 20.04.7929-Apr-2408-May-24
Three Month10.43 20.33 % 5.95 % 20.04.7929-Apr-2408-May-24
Six Months6.07 36.90 % 17.48 % 22.494.7927-Dec-2308-May-24
One year13.59 38.85 % 27.52 % 22.494.7927-Dec-2308-May-24
Two year9.77 14.94 % 29.70 % 23.894.7929-Mar-2308-May-24


Technical View of Annovis Bio Inc
RSI

49.71

Neutral
MACD

-0.724

Mild Bullish
ADX

18.53

Neutral
Super Trend

10.22

Mild Bearish
Williams %R

-37.25

Neutral
CCI

-8.62

Neutral


EMA 5

7.89

Bullish
EMA 15

7.74

Strong Bullish
EMA 50

9.14

Mild Bearish
EMA 100

9.80

Strong Bearish
SMA 100

10.69

Bearish
SMA 200

10.18

Mild Bearish
SMA 5 / 20

8.05 / 8.26

Mild Bearish
SMA 15 / 50

6.49 / 9.70

Strong Bearish
SMA 50 / 200

9.70 / 10.18

Mild Bearish




Charts of Annovis Bio Inc


Returns of Annovis Bio Inc with Peers
Period / StockANVSETONMIROMIST
1 Week40.13%5.54%-0.294%2.35%
1 Mth-7.56%15.29%0.296%-0.571%
3 Mth-20.33%-17.73%158.78%13.73%
6mth36.90%2.26%111.87%-20.91%
1 Year-38.85%-1.90%-17.32%-56.61%
2 Year-14.94%10.70%-47.77%-69.09%
5 Years--56.39%--90.70%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Annovis Bio Inc with Peers
Ratio / StockANVSETONMIROMIST
PE-0.0075102.22-3.19-340.04
P/B0.02296.152.64521.69
ROA-173.443.07-63.43-59.05
ROE-305.646.02-82.78-153.42
Debt To Equity00.3510.03143.00
Revenue0
% 		32827.00 K
54.47 % 		953470
2783.54 % 		4500.00 K
10.00 %
Net Income-41717.09 K
65.90 % 		2232.00 K
124.74 % 		-29960.00 K
104.22 % 		-59251.00 K
3.71 %


Technicals of Annovis Bio Inc with Peers
Technical / StockANVSETONMIROMIST-
ADX18.5314.6862.5918.77
CMF-0.311-0.3670.056-0.062
MFI54.1234.0376.1063.38
RSI49.7152.1975.3255.95
MACD Abv SignalTrueTrueFalseTrue
Price Above 50 MAFalseFalseTrueTrue-
Price Above 200 MAFalseFalseTrueFalse-


About : Annovis Bio Inc

Address : 1055 Westlakes Drive, Berwyn, PA, United States, 19312
Tel : 610 727 3913
URL : https://www.annovisbio.com
Code : ANVS, ISIN : US03615A1088, Exchange : NYSE, Country : USA
Fiscal Year End : December
IPO date : 12_Feb_2010
Employee Count : 6

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.


Note : All Data Generated at the End of Trading Hours (EOD Data)